Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
TACE plus atezolizumab + bevacizumab versus TACE alone in previously untreated hepatocellular carcinoma
CTR20202073Phase 3Active
- Sponsor
- Roche
- Start
- Mar 2021
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics, Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
A Phase 3 trial of atezolizumab, bevacizumab in hepatocellular carcinoma (HCC), sponsored by Roche. Started Mar 2021; status: active.
02
Drugs
atezolizumabbevacizumab
03
Conditions
hepatocellular carcinoma (HCC)
Beyond the preview
Go deeper on CTR20202073.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20202073.